Published in final edited form as:

Biomaterials. 2010 February ; 31(6): 1372. doi:10.1016/j.biomaterials.2009.10.045.

The delivery of superoxide dismutase encapsulated in polyketal microparticles to rat myocardium and protection from myocardial ischemia-reperfusion injury

Gokulakrishnan Seshadri¹, Jay C. Sy¹, Milton Brown¹, Sergey Dikalov², Stephen C. Yang¹, Niren Murthy¹, and Michael E. Davis^{1,2,*}

¹Wallace H. Coulter Department of Biomedical Engineering at Emory University and Georgia Institute of Technology, Atlanta, GA 30322

²Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia 30322

Abstract

Oxidative stress is increased in the myocardium following infarction and plays a significant role in death of cardiac myocytes, leading to cardiac dysfunction. Levels of the endogenous antioxidant Cu/Zn-superoxide dismutase (SOD1) decrease following myocardial infarction. While SOD1 gene therapy studies show promise, trials with SOD1 protein have had little success due to poor pharmacokinetics and thus new delivery vehicles are needed. In this work, polyketal particles, a recently developed delivery vehicle, were used to make SOD1-encapsulated-microparticles (PKSOD). Our studies with cultured macrophages demonstrated that PKSOD treatment scavenges both intracellular and extracellular superoxide, suggesting efficient delivery of SOD1 protein to the inside of cells. In a rat model of ischemia/reperfusion (IR) injury, injection of PKSOD, and not free SOD1 or empty particles was able to scavenge IR-induced excess superoxide 3 days following infarction. In addition, only PKSOD treatment significantly reduced myocyte apoptosis. Further, PKSOD treatment was able to improve cardiac function as measured by acute changes in fractional shortening from baseline echocardiography, suggesting that sustained delivery of SOD1 is critical during the early phase of cardiac repair. These data demonstrate that delivery of SOD1 with polyketals is superior to free SOD1 protein therapy and may have potential clinical implications.

Keywords

Antioxidant; microencapsulation; free radical; apoptosis

© 2009 Elsevier Ltd. All rights reserved.

*To whom correspondence should be addressed: Michael E. Davis, Ph.D, Assistant Professor of Biomedical Engineering and Medicine, The Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, 101 Woodruff Circle, Suite 2001, Atlanta, GA 30322, USA, michael.davis@bme.emory.edu, Telephone: (404) 727-9858, Fax: (404) 727-9873

Conflict of Interest

The authors report no conflict of interest.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1. Introduction

Ischemic heart diseases, leading to myocardial infarction and heart failure, are a leading cause of global morbidity and mortality [1]. Loss of myocytes through necrosis and programmed cell death (apoptosis) following insults such as ischemia/reperfusion (IR) is mainly regional [2], suggesting the potential benefit of a localized therapy in preventing the development of cardiac dysfunction. However, because the disease is progressive in nature, localized therapy must also be sustained to deliver a consistent amount of drug over relevant times. Oxidative stress has been proposed as the unifying mechanism behind various risk factors of heart diseases [3] and it is implicated in many pathological disease states of the heart including hypertrophy [4], IR injury [5] and myocardial stunning [6]. Thus, a therapy that could address the high oxidative radicals over a sustained period of time will have great potential in prevention of cardiac dysfunction.

Direct measurements and indirect inferences have implicated the role of excess superoxide levels in the pathogenesis of infarct development, reperfusion injury and eventual myocardial dysfunction [7,8]. Additionally, mRNA expression levels of superoxide dismutase (SOD), an endogenous superoxide scavenger, decrease significantly after myocardial infarction thereby potentially exacerbating superoxide levels [9]. Antioxidant therapy with SOD including transgenic overexpression and gene therapy studies improve cardiac function following infarction, but the clinical relevance of these studies is still unclear as questions still remain regarding the safety and efficacy of gene therapy [10,11].

Despite the large role of oxidative stress in cardiac dysfunction, there is a strong lack of consistency in the efficacy of Cu/Zn SOD (SOD1) protein therapy and many large animal trials have failed to show a significant benefit [12,13]. Possible factors contributing to these discrepancies are the unfavorable pharmacokinetics and the rapid protein half-life of SOD1. Half life of circulating wild type bovine SOD1 in rat blood is about six minutes [14] and depending on the modifications made to the protein, its half life can increase to about six hours [14-16]. Thus, there is significant interest in developing better SOD delivery systems, and many modifications have been made to the SOD protein to improve its pharmacokinetics and delivery including addition of cell penetrating molecules and targeting sequences [17]. Although, these modified proteins have better efficacies than the native SOD protein, intracellular delivery of the drug remains a challenge. In addition, high doses of these modified SODs are used in most studies [17] which by itself can exacerbate the cardiac pathologies [18].

The goal of the present study was to demonstrate that a direct myocardial injection of SOD1 encapsulated within polyketal microparticles can reduce both extracellular and intracellular superoxide levels, generate a sustained level of SOD1 within the myocardium and improve the cardiac function following IR injury. Here poly(cyclohexane-1,4diyl acetone dimethylene ketal) (PCADK) – a recently developed polymer – was used as a delivery vehicle for SOD1 protein.

2. Materials and methods

2.1 PKSOD and empty PCADK (PK) particle preparation

PKSOD particles were made by a double emulsion process as described by Lee *et al.* [19] with slight modifications. In our method, a protein to polymer ratio of 0.05 was taken and larger particles were created by stirring the water in oil emulsion at 6000 rpm for one minute. PK particles were made in a similar manner without the addition of SOD1 protein. PCADK microparticles encapsulating a p38 inhibitor (SB239063) (PK-p38i) was made as described previously [20]. Fluorescein isothiocyanate (FITC) conjugated SOD (FSOD) was made by stirring SOD1 (5 mg/ ml pH 9.0 carbonate buffer) with FITC (1 mg/ml DMSO) overnight at

4°C. The conjugated protein was purified by dialysis (8k molecular weight cutoff) and lyophilized and fluorescent FSOD loaded PK particles (PKFSOD) were made similarly as described above.

2.2 Macrophage culture

RAW264.7 macrophages were maintained in DMEM (Fisher) supplemented with 10% fetal bovine serum (Hyclone), l-glutamine, and penicillin/streptomycin (Invitrogen). For experiments involving PMA stimulation, cells were seeded on a 12 well plate (2 million cells/well) and quiesced overnight in serum free DMEM. The media was then aspirated and replaced with treatment media (Kreb's Hepes buffer (KHB)) containing SOD1 (50 U), PKSOD or PK, and incubated for 5 hr at 37 °C. Cells were then washed with ice cold KHB buffer followed by the addition of media with or without 10 µM PMA for 20 min at 37 °C.

2.3 Intracellular and extracellular superoxide measurement

Superoxide was detected using dihydroethidium (DHE) and a high-performance liquid chromatography (HPLC) based assay [21]. In the cell culture experiments, macrophages were stimulated with 10 µM PMA along with 20 µM DHE and incubated at 37 °C for 20 minutes protected from light. For extracellular superoxide measurement, 100 µl of reaction buffer was removed and suspended in 300 µl methanol. For intracellular superoxide measurement, the cells were mechanically homogenized and suspended in 300 µl methanol. In order to separate ethidium, oxyethidium and unreacted DHE, the samples were loaded on a C18 column for reverse-phase HPLC analysis using an acetonitrile gradient [21].

2.4 Animals

A randomized and blinded study was conducted using adult Sprague-Dawley rats (obtained from Charles River) weighing 250 g. Rats were divided into two time points (3 and 21 days) containing five groups (n = 7 to 10 per group) each. While one group was subjected to sham surgery, the other four groups received IR surgery (30 min. coronary artery ligation followed by reperfusion), with or without the injection of 100 µl of saline containing either 80U SOD1, 10 mg/ml of PK or 10 mg/ml PKSOD with or without 5 mg/ml SB239063 (p38 inhibitor), into the perimeter of cyanotic ischemic zone (3 locations) through a 30-gauge needle immediately after reperfusion. The animals were sacrificed after the specific time point and the hearts were molded in OCT compound and snap frozen in liquid nitrogen.

The investigation conformed with the *Guide for the Care and Use of Laboratory Animals* published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) and all animal studies were approved by Emory University Institutional Animal Care and Use Committee.

2.5 Superoxide detection following IR

In situ superoxide production was detected using DHE as described previously with slight modifications [22]. Briefly, 10 µM DHE was topically applied over unfixed frozen 20 µm heart sections and incubated at 37 °C in a light protected CO₂ incubator for 5 minutes. After 2 minutes of DAPI staining, the slides were mounted with antifading medium (Vectashield® HardSet™; Vector laboratories) and analyzed with Axioscope fluorescence microscope with identical camera acquisition settings [8]. DHE fluorescence intensity was quantified using ImageJ software (NIH).

2.6 Apoptosis detection

Roche Diagnostics TUNEL (terminal transferase-mediated dUTP-fluorescein nick end labeling) assay kit was used as per the manufacturer's protocol to determine the number of

apoptotic cells in the tissue sample. The slides were imaged using Axioscope fluorescence microscope and the number of TUNEL positive cells among the myocytes was reported as a percentage.

2.7 Echocardiography

Anesthetized rats were subjected to echocardiography prior to and after 3 or 21 days of IR surgery. Short axis values of left ventricular end systolic (ES) and end diastolic (ED) dimension were obtained using Acuson Sequoia 512 echocardiography workstation with 14 MHz transducer. An average of 2 consecutive cardiac cycles was used for each measurement and were made three times in an investigator-blinded manner. Changes in fractional shortening (calculated as (ED-ES)/ED) were determined after normalizing each rat to its own baseline value.

2.8 Statistics

All statistical analyses were performed using Graphpad Prism software as described in the figure legends. P values of less than 0.05 were considered significant.

3. Results

3.1 SOD encapsulation within PCADK microparticles

A double emulsion method was used to encapsulate SOD within the PCADK particles (PKSOD). Particle analysis with ImageJ software revealed that the size ranged from about 2 μm to 30 μm with a mean particle size of $11.4 \pm 4.9 \mu\text{m}$ (Figure 1A bottom panel). Representative SEM images are shown in Figure 1B. Empty particles (PK) were similar in size and morphology to PKSOD particles ($10.8 \pm 5.9 \mu\text{m}$, Figure 1A top panel). Micro-BCA protein analysis of the encapsulated protein revealed an encapsulation efficiency of 50% (expressed as the ratio of actual SOD1 loading to the theoretical maximum), corresponding to almost 100 U of SOD1 per mg of polymer (Figure 1C).

3.2 In vitro superoxide scavenging

The ability of PKSOD particles to scavenge superoxide radicals was investigated in macrophage cell culture (RAW 264.7) using quantitative DHE-HPLC. PMA stimulation resulted in a 1.6-fold increase in extracellular superoxide production as compared to control cells ($p < 0.01$). This increase was significantly inhibited by application of exogenous SOD1 (50 U/mL) ($p < 0.001$; Figure 2A). Cells pretreated with PK particles also showed a significant PMA-induced increase in superoxide levels ($p < 0.01$ vs vehicle treated control), whereas cells treated with PKSOD for 5 hours prior to PMA-stimulation had no significant increase in superoxide levels compared to control cells. This inhibition was evident at both 0.25 mg and 0.125 mg of polymer per million cells (Figure 2A).

Analysis of intracellular superoxide levels revealed that PMA stimulation significantly increased superoxide levels 3.9-fold as compared to control cells ($p < 0.01$). In contrast to the results observed in extracellular superoxide measurement, treatment with exogenous SOD1 was not able to reduce PMA-induced intracellular superoxide production (Figure 2B, $p < 0.001$ vs control). Similarly, PK pretreatment also had no significant effect on intracellular superoxide levels ($p < 0.01$ vs. vehicle treated control; Figure 2B). Interestingly, PKSOD pretreatment was able to dose-dependently reduce the PMA-induced intracellular superoxide levels (Figure 2B), suggesting efficient delivery of SOD1 to the intracellular space.

3.3 PKSOD retention in the myocardium

In order to determine the ability of PKSOD to remain in the heart after IR, either fluorescent SOD1 (FSOD) or PKFSOD were injected intramyocardially (n=3) and analyzed by confocal microscopy three days following IR surgery (Figure 3). Three-dimensional reconstruction of images showed bright fluorescence from PKFSOD particles scattered in the left ventricular infarct zone of the myocardium (Figure 3A) with no fluorescence in the non-infarcted tissue (data not shown). Additionally, data obtained in our laboratory demonstrates retention of the particles for up to 10 days in native myocardium [20]. This fluorescence was totally absent in FSOD injected hearts (Figure 3B).

3.4 In vivo superoxide scavenging

In preliminary studies, we found a significant increase in superoxide production at 3 days following IR that was completely inhibited by PKSOD treatment as measured by cytochrome C reduction (supplemental data) with no measurable increase in superoxide at 7 days (data not shown). To better localize the superoxide generation/scavenging, DHE-based in situ superoxide detection was performed as described in methods. Our results show that superoxide levels were significantly increased in the border zones of the ischemic left ventricular region ($p<0.05$). Treatment with PK or free SOD1 protein was not able to reduce the increase in DHE fluorescence while PKSOD treatment was able to significantly ($P<0.05$) reduce it to basal levels (Figure 4). Examination of the infarct core demonstrated no significant increase in DHE fluorescence with IR (data not shown).

3.5 Myocyte apoptosis following IR

In order to measure apoptosis, rats subjected to different treatments were sacrificed after three days and TUNEL staining was performed on 5 μ m frozen sections and the percentage of TUNEL positive myocytes were determined by manual counting in a blinded manner. IR injury significantly ($p<0.05$) increased the percentage of TUNEL positive myocytes within the left ventricle infarct zone greater than 4-fold as compared to sham operated animals. There was no significant decrease in apoptosis with either PK or free SOD1 treatment; however, PKSOD treatment significantly ($p<0.05$) reduced the TUNEL-positive myocyte count (Figure 5).

3.6 Cardiac function following IR

To determine the effect of sustained SOD delivery on cardiac function, echocardiography data was collected prior to surgery to determine basal function, and then again after indicated time points (3 and 21 days post-surgery) as described in methods. As shown in Figure 6A, IR significantly reduced cardiac function ($p<0.05$) as measured in absolute change in fractional shortening from baseline to 3 days post-injury. While there was no effect of free SOD1 or empty PK, treatment with PKSOD significantly ($p<0.05$) improved function to sham levels. Similarly, IR-injury significantly impaired chronic cardiac function as measured by absolute change in fractional shortening from baseline to 21 days ($p<0.01$). Although a similar trend was observed with cardiac functional improvement seen in PKSOD treated animals as compared to PK or free SOD1, the rats were not significantly improved compared with IR alone. Thus, we investigated whether dual delivery with particles containing a p38 inhibitor (PK-p38_i) that, in prior published studies had no acute effect but improved chronic cardiac function due to inhibition of fibrosis [20], could improve function in these rats. Interestingly, dual treatment with PKSOD and PK-p38_i significantly improved cardiac function compared to IR alone, suggesting the need for multiple therapeutics to combat the different phases of the disease ($p<0.05$).

4. Discussion

The overproduction of superoxide plays a central role in the progression of ischemia/reperfusion (IR) injury and causes a rapid loss of cardiomyocytes and decreased cardiac function. In spite of convincing studies on the role of superoxide in causing cardiac pathologies and the ability of SOD1 to reverse this [11,23], conflicting results exist on the efficacy of SOD treatment [12,24] likely due to its poor stability. Our primary findings indicate that PCADK microparticles can be used for sustained and intracellular delivery of SOD1 protein which improves cardiac function during the acute phase of reperfusion injury.

In this report, PCADK – a polyketal based biodegradable polymer – was used as a carrier to deliver SOD1 to scavenge both intra- and extra- cellular superoxide. Unlike polyester based biomaterials, these polymers do not have acidic degradation products [25] and their potential to encapsulate SOD has been reported previously [19]. Importantly, PCADK causes no significant inflammatory response and we have recently demonstrated its ability to treat inflammatory diseases like cardiac dysfunction with small molecule anti-inflammatory drugs making it an ideal carrier for in vivo applications [20]. Particle size analysis revealed that PKSOD microparticles in 2 to 30 μm size range can be made using a double emulsion method by employing low speeds during the homogenization step. This size distribution allows the particles to be retained by a single injection in vascular tissues such as the myocardium, while still having particles small enough to be taken up by macrophages. Published data demonstrates that SOD1 protein maintains its activity following encapsulation [19] and our data show that we can successfully encapsulate SOD1 into larger particles more suitable for cardiac delivery.

Superoxide generation occurs both inside and outside of cells during IR and we therefore measured the effects of PKSOD on both intracellular and extracellular superoxide production. Our results were not surprising for free SOD1, as our data demonstrate its ability to only scavenge extracellular superoxide, as large proteins do not cross the cell membrane. In stark contrast, our PKSOD particles were able to significantly reduce superoxide levels intra- and extracellularly, suggesting the particles were taken up by the macrophages and the contents released intact within. Our unpublished data suggests that active processes are involved in uptake of the particles as inhibitors of phagocytosis and endocytosis partially inhibit uptake (data not shown). This finding suggests potential advantages of PKSOD over other SOD delivery vehicles, as intracellular superoxide buildup cannot be adequately addressed by a simple parenteral administration of SOD1 as it requires modifications to increase cell permeability, such as coupling it to polyethylene glycol (PEG). Not only does this entail more synthetic steps, but PEG itself may induce an oxidative response [26]. Scavenging excess superoxide levels within macrophages is known to reduce production of inflammatory cytokines such as tumor necrosis factor alpha [27] which causes damage to native cardiomyocytes [28]. Other cell types such as endothelial cells and cardiac stem cells also internalize these particles (data not shown) and a reduction of superoxide build up in different cell types in the myocardium may have additional beneficial effects.

The heart is a highly vascularized organ and as such most small molecules and proteins are rapidly cleared [29]. Therefore, many therapies usually involve daily or multiple injections of drugs and proteins over extended time periods [30,31]. Although gene therapy could provide a solution for this problem [32], targeting specific tissues and cell types is very difficult through this method. Further, prolonged overexpression of drugs such as SOD1 could exacerbate cardiac pathologies [18]. Intracellular delivery of SOD1 using cell penetrating peptides may protect the myocardium against ischemic insult [33] however through this method the protein was delivered systemically, increasing the chances for nonspecific effects and protein loss. Thus given the fact that intramyocardial injections are considered safe [34], a one-time localized administration of drugs that could sustain antioxidant levels in the heart during

disease progression could offer advantage over existing treatment methods. To determine whether our micron-sized particles were retained in the heart, we initially created fluorescent dye (rubrene) loaded particles and injected them directly in to healthy myocardium. Confocal microscopy showed the particles to be scattered in the myocardium three days following surgery and even over a week later [20]. Additionally, our prior studies demonstrated that the half life of these particles was quite stable in neutral environments with no inflammatory response, thus we expect the particles to be quite stable for several weeks in the myocardium [19,20]. We then tested the retention of PKSOD particles in ischemic myocardium by injecting fluorescent PKFSOD or FSOD intramyocardially following IR. The confocal images clearly show the local retention of PKFSOD in the myocardium three days after IR surgery.

To determine the effect of prolonged SOD1 retention with polyketals, we injected the PKSOD particles in a randomized and blinded study to the myocardium of IR-injured rats, injecting treatments immediately after reperfusion. Our data show that 3 days following IR, excess superoxide is generated in the border zones of the ischemic left ventricle. This increase in superoxide is not affected by administration of free SOD1 protein, but completely inhibited by intramyocardial injection of PKSOD several days after injection. This finding is striking not only due to the prolonged effect of PKSOD administration, but also because of the dose given (single injection of 1 mg per rat, corresponding to 80U of SOD1). This dose is several orders of magnitude lower than previous published reports demonstrating infusion of over 1,000U/kg prior to infarction followed by continuous infusion of over 1,000U/kg thereafter [35]. We speculate that our treatment was more effective due to the localized nature of the superoxide generation (border zones only) and the fact that our microparticles are retained within the injection site. These conclusions are supported by our imaging data demonstrating that the native protein is not retained in the myocardium following injection. Thus, large doses of free SOD1 would be needed to maintain pharmacologically relevant doses in the affected area.

Superoxide generation is known to cause cardiomyocyte apoptosis [36], which is generally held to be responsible for progressive loss of cardiomyocytes after IR in spite of wide variations in the percentage of apoptotic myocytes (0.05 to 35%) [37,38]. The majority of cardiomyocyte apoptosis occurs within the first 72 hours of reperfusion, thus we hypothesized that the sustained reduction of superoxide by PKSOD administration would be beneficial in reducing early cardiomyocyte apoptosis. Interestingly only PKSOD treatment significantly reduced cardiomyocyte apoptosis, suggesting that prolonged superoxide scavenging plays an important role in the survival of endogenous cardiomyocytes. This is in contrast to some studies showing free SOD1 infusion reduces apoptosis and infarct size, however it should be noted that the levels used to correspond to our PKSOD treatment (80U) were much lower than levels used in those studies. Finally, we examined the effect of prolonged superoxide scavenging by PKSOD on cardiac function measured by echocardiography. Change in fractional shortening from baseline echocardiograms demonstrated a significant improvement in function due to PKSOD treatment three days following treatment, with function similar to sham operated animals. In contrast, no functional improvements were observed with free SOD1 or PK treatment suggesting a critical need for sustained therapy. Our apoptosis data show a low percentage of apoptotic cells (about 0.5%) after IR and a reduction of that percentage to about 0.1% by PKSOD treatment was able to show a significant functional recovery. Whereas inhibiting initial apoptosis is critical in maintaining normal function and homeostasis, we speculate that the sustained inhibition of superoxide levels may play important role outside of cell survival, such as improving vasculogenesis [39], expression of contractile proteins [40] and recruitment of regenerative cells [39]. Current studies are underway to examine whether prolonged SOD1 presence induces migration of regenerative cells that may aid in functional recovery.

During the chronic phase (21 days following IR), no significant improvement in cardiac function was observed with PKSOD. Though there was a trend toward improved function with PKSOD treatment (30% better than IR alone) as compared to PK and free SOD1, this result did not achieve statistical significance. It is entirely possible that the PKSOD was completely consumed in the early phase and a supplement dose would be needed later. It may also be possible that increased superoxide alone does not determine the fate of orchestrated set of events happening in myocardial disease progression. Thus a single antioxidant alone may not be sufficient to rescue function in the chronic phase of disease development. Supporting this, our recent study using polyketals to deliver small molecule inhibitors demonstrated no acute effect of p38 pathway inhibition, though sustained delivery had a striking effect on chronic remodeling. To address this interesting possibility, we delivered both PKSOD and PK-p38_i following reperfusion and measured function at baseline and 21 days following injury. The combined treatment significantly improved cardiac function as compared to IR alone, suggesting the potential need for multiple therapies to treat this progressive disease. Current studies are underway to understand the various mechanistic processes in different phases of myocardial infarction and making modifications to the polyketals to allow for delivery of multiple factors.

5. Conclusion

In summary our work demonstrates that PCADK microparticles can be used as a carrier for sustained and intracellular delivery of SOD1. SOD encapsulation within PCADK improves the duration of superoxide scavenging following ischemia/reperfusion injury. Prior SOD1 protein therapy for myocardial infarction was inconclusive, involving repeated administration of large quantities of the enzyme. Unlike other modifications made to SOD1 to improve stability, encapsulation within PCADK also allows for intracellular delivery, an important factor as intracellular superoxide production may account for a significant proportion of superoxide generated following injury. This sustained scavenging of superoxide led to increased cardiomyocyte survival following injury and ultimately preserved cardiac function. These results may have broad clinical implications in treatment of cardiac dysfunction and other diseases where sustained oxidative stress contributes to pathology.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Debi Martinson and Lu Hilenski (Emory Imaging Core) for their help and support for our microscopy studies.

Funding

This work was supported by grants from National Institutes of Health (HL089120 and HL090601; MED), UO1 HL80711-01 (MED, NM), EB006418 (NM), the Georgia Tech/Emory Center for the Engineering of Living Tissues (funded by National Science Foundation-EEC-9731643; NM), J&J/GT Health Care Innovation Seed Grant Proposal (NM) and the Department of Homeland Security (DHS) Scholarship and Fellowship Program, administered by the Oak Ridge Institute for Science and Education (ORISE) through an interagency agreement between the US Department of Energy (DOE) and DHS (JCS). ORISE is managed by Oak Ridge Associated Universities (ORAU) under DOE contract number DE-AC05-06OR23100. All opinions expressed in this paper are the authors' and do not necessarily reflect the policies and views of DHS, DOE or ORAU/ORISE.

References

- [1]. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. *PLoS Med* 2006;3:e442. [PubMed: 17132052]

- [2]. Buja LM, Vela D. Cardiomyocyte death and renewal in the normal and diseased heart. *Cardiovasc Pathol* 2008;17:349–74. [PubMed: 18402842]
- [3]. Madamanchi, NR.; Runge, MS. Oxidative Stress. In: Runge, MS.; Patterson, C., editors. *Principles of Molecular Cardiology*. Humana Press; 2005. p. 549-61.
- [4]. Nakamura K, Fushimi K, Kouchi H, Mihara K, Miyazaki M, Ohe T, et al. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor- α and angiotensin II. *Circulation* 1998;98:794–9. [PubMed: 9727550]
- [5]. Ferrari R, Alfieri O, Curello S, Ceconi C, Cargnoni A, Marzollo P, et al. Occurrence of oxidative stress during reperfusion of the human heart. *Circulation* 1990;81:201–11. [PubMed: 2297827]
- [6]. Li XY, McCay PB, Zughaib M, Jeroudi MO, Triana JF, Bolli R. Demonstration of free radical generation in the “stunned” myocardium in the conscious dog and identification of major differences between conscious and open-chest dogs. *J Clin Invest* 1993;92:1025–41. [PubMed: 8394382]
- [7]. Bolli R, Jeroudi MO, Patel BS, DuBose CM, Lai EK, Roberts R, et al. Direct evidence that oxygen-derived free radicals contribute to postischemic myocardial dysfunction in the intact dog. *Proc Natl Acad Sci U S A* 1989;86:4695–9. [PubMed: 2543984]
- [8]. Ambrosio G, Becker LC, Hutchins GM, Weisman HF, Weisfeldt ML. Reduction in experimental infarct size by recombinant human superoxide dismutase: insights into the pathophysiology of reperfusion injury. *Circulation* 1986;74:1424–33. [PubMed: 3779923]
- [9]. Khaper N, Kaur K, Li T, Farahmand F, Singal PK. Antioxidant enzyme gene expression in congestive heart failure following myocardial infarction. *Mol Cell Biochem* 2003;251:9–15. [PubMed: 14575298]
- [10]. Li Q, Bolli R, Qiu Y, Tang XL, Guo Y, French BA. Gene therapy with extracellular superoxide dismutase protects conscious rabbits against myocardial infarction. *Circulation* 2001;103:1893–8. [PubMed: 11294809]
- [11]. Wang P, Chen H, Qin H, Sankarapandi S, Becher MW, Wong PC, et al. Overexpression of human copper, zinc-superoxide dismutase (SOD1) prevents postischemic injury. *Proc Natl Acad Sci U S A* 1998;95:4556–60. [PubMed: 9539776]
- [12]. Uraizee A, Reimer KA, Murry CE, Jennings RB. Failure of superoxide dismutase to limit size of myocardial infarction after 40 minutes of ischemia and 4 days of reperfusion in dogs. *Circulation* 1987;75:1237–48. [PubMed: 3568330]
- [13]. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part II: animal and human studies. *Circulation* 2003;108:2034–40. [PubMed: 14581381]
- [14]. Hallewell RA, Laria I, Tabrizi A, Carlin G, Getzoff ED, Tainer JA, et al. Genetically engineered polymers of human CuZn superoxide dismutase. *Biochemistry and serum half-lives*. *J Biol Chem* 1989;264:5260–8. [PubMed: 2647749]
- [15]. Ogino T, Inoue M, Ando Y, Awai M, Maeda H, Morino Y. Chemical modification of superoxide dismutase. Extension of plasma half life of the enzyme through its reversible binding to the circulating albumin. *Int J Pept Protein Res* 1988;32:153–9. [PubMed: 3220661]
- [16]. Regnault C, Soursac M, Roch-Arveiller M, Postaire E, Hazebroucq G. Pharmacokinetics of superoxide dismutase in rats after oral administration. *Biopharm Drug Dispos* 1996;17:165–74. [PubMed: 8907723]
- [17]. Muzykantov VR. Targeting of superoxide dismutase and catalase to vascular endothelium. *J Control Release* 2001;71:1–21. [PubMed: 11245904]
- [18]. Omar BA, Gad NM, Jordan MC, Striplin SP, Russell WJ, Downey JM, et al. Cardioprotection by Cu,Zn-superoxide dismutase is lost at high doses in the reoxygenated heart. *Free Radic Biol Med* 1990;9:465–71. [PubMed: 1964145]
- [19]. Lee S, Yang SC, Heffernan MJ, Taylor WR, Murthy N. Polyketal microparticles: a new delivery vehicle for superoxide dismutase. *Bioconjug Chem* 2007;18:4–7. [PubMed: 17226951]
- [20]. Sy JC, Seshadri G, Yang SC, Brown M, Oh T, Dikalov S, et al. Sustained release of a p38 inhibitor from non-inflammatory microspheres inhibits cardiac dysfunction. *Nat Mater* 2008;7:863–8. [PubMed: 18931671]
- [21]. Fink B, Laude K, McCann L, Doughan A, Harrison DG, Dikalov S. Detection of intracellular superoxide formation in endothelial cells and intact tissues using dihydroethidium and an HPLC-based assay. *Am J Physiol Cell Physiol* 2004;287:C895–902. [PubMed: 15306539]

- [22]. Collin B, Busseuil D, Zeller M, Perrin C, Barthez O, Duvillard L, et al. Increased superoxide anion production is associated with early atherosclerosis and cardiovascular dysfunctions in a rabbit model. *Mol Cell Biochem* 2007;294:225–35. [PubMed: 16871360]
- [23]. Tanaka M, Mokhtari GK, Terry RD, Balsam LB, Lee KH, Kofidis T, et al. Overexpression of human copper/zinc superoxide dismutase (SOD1) suppresses ischemia-reperfusion injury and subsequent development of graft coronary artery disease in murine cardiac grafts. *Circulation* 2004;110:II200–6. [PubMed: 15364863]
- [24]. Jolly SR, Kane WJ, Bailie MB, Abrams GD, Lucchesi BR. Canine myocardial reperfusion injury. Its reduction by the combined administration of superoxide dismutase and catalase. *Circ Res* 1984;54:277–85. [PubMed: 6697450]
- [25]. Heffernan MJ, Murthy N. Polyketal nanoparticles: a new pH-sensitive biodegradable drug delivery vehicle. *Bioconjug Chem* 2005;16:1340–2. [PubMed: 16287226]
- [26]. Zhao L, He J, Wang X, Zhang L. Nitric oxide protects against polyethylene glycol-induced oxidative damage in two ecotypes of reed suspension cultures. *J Plant Physiol* 2008;165:182–91. [PubMed: 17499387]
- [27]. Ndengele MM, Muscoli C, Wang ZQ, Doyle TM, Matuschak GM, Salvemini D. Superoxide potentiates NF-kappaB activation and modulates endotoxin-induced cytokine production in alveolar macrophages. *Shock* 2005;23:186–93. [PubMed: 15665736]
- [28]. Kaur K, Sharma AK, Dhingra S, Singal PK. Interplay of TNF-alpha and IL-10 in regulating oxidative stress in isolated adult cardiac myocytes. *J Mol Cell Cardiol* 2006;41:1023–30. [PubMed: 17045606]
- [29]. Davis ME, Hsieh PC, Grodzinsky AJ, Lee RT. Custom design of the cardiac microenvironment with biomaterials. *Circ Res* 2005;97:8–15. [PubMed: 16002755]
- [30]. Jadot G, Vaille A, Maldonado J, Vanelle P. Clinical pharmacokinetics and delivery of bovine superoxide dismutase. *Clin Pharmacokinet* 1995;28:17–25. [PubMed: 7712659]
- [31]. Sinha VR, Trehan A. Biodegradable microspheres for protein delivery. *J Control Release* 2003;90:261–80. [PubMed: 12880694]
- [32]. Agrawal RS, Muangman S, Layne MD, Melo L, Perrella MA, Lee RT, et al. Pre-emptive gene therapy using recombinant adeno-associated virus delivery of extracellular superoxide dismutase protects heart against ischemic reperfusion injury, improves ventricular function and prolongs survival. *Gene Ther* 2004;11:962–9. [PubMed: 15029230]
- [33]. Zhang YE, Wang JN, Tang JM, Guo LY, Yang JY, Huang YZ, et al. In vivo protein transduction: delivery of PEP-1-SOD1 fusion protein into myocardium efficiently protects against ischemic insult. *Mol Cells* 2009;27:159–66. [PubMed: 19277497]
- [34]. Mearns BM. Intramyocardial injections are safe. *Nat Rev Cardiol* 2009;6:441.
- [35]. Chi LG, Tamura Y, Hoff PT, Macha M, Gallagher KP, Schork MA, et al. Effect of superoxide dismutase on myocardial infarct size in the canine heart after 6 hours of regional ischemia and reperfusion: a demonstration of myocardial salvage. *Circ Res* 1989;64:665–75. [PubMed: 2702730]
- [36]. Li PF, Dietz R, von Harsdorf R. Superoxide induces apoptosis in cardiomyocytes, but proliferation and expression of transforming growth factor-beta1 in cardiac fibroblasts. *FEBS Lett* 1999;448:206–10. [PubMed: 10218477]
- [37]. Cheng W, Kajstura J, Nitahara JA, Li B, Reiss K, Liu Y, et al. Programmed myocyte cell death affects the viable myocardium after infarction in rats. *Exp Cell Res* 1996;226:316–27. [PubMed: 8806435]
- [38]. Palojoki E, Saraste A, Eriksson A, Pulkki K, Kallajoki M, Voipio-Pulkki LM, et al. Cardiomyocyte apoptosis and ventricular remodeling after myocardial infarction in rats. *Am J Physiol Heart Circ Physiol* 2001;280:H2726–31. [PubMed: 11356629]
- [39]. Ceradini DJ, Yao D, Grogan RH, Callaghan MJ, Edelstein D, Brownlee M, et al. Decreasing intracellular superoxide corrects defective ischemia-induced new vessel formation in diabetic mice. *J Biol Chem* 2008;283:10930–8. [PubMed: 18227068]
- [40]. Costa VM, Silva R, Tavares LC, Vitorino R, Amado F, Carvalho F, et al. Adrenaline and reactive oxygen species elicit proteome and energetic metabolism modifications in freshly isolated rat cardiomyocytes. *Toxicology* 2009;260:84–96. [PubMed: 19464573]

Figure1. SOD can be encapsulated within Poly(cyclohexane-1,4-diyl acetone dimethylene ketone) to create micron sized particles

(A) Histogram of the microparticles analyzed with ImageJ software demonstrating similar size distribution. (B) SEM image of empty polymer (PK) and PKSOD (Scale bar: 20 μm). (C) SOD1 protein encapsulated in PKSOD as measured by micro-BCA method.

Figure 2. PKSOD microparticles effectively scavenge extra- and intracellular superoxide
 Superoxide production from phorbol 12-myristate 13-acetate (PMA)-stimulated cultured macrophages was measured by quantitative HPLC. (A) Extracellular superoxide concentration from media per one million cells. Only SOD1 (white bar) and PKSOD were able to significantly reduce PMA-induced extracellular superoxide production in cultured macrophages. (B) Intracellular superoxide per mg protein represented. Only PKSOD significantly reduced the PMA induced intracellular superoxide levels. Results are normalized with respect to control and grouped data are an average of four experiments and shown as mean $\pm$ SEM. ** $p < 0.01$, *** $p < 0.001$, NS = not significant; ANOVA followed by Tukey-Kramer post-test.

Figure 3. PKSOD microparticles are retained in the heart

Three-dimensional rendering of a confocal fluorescent microscope image of infarcted myocardium section injected with either free FITC-SOD1 (FSOD) or polyketal-encapsulated FITC-SOD1 (PKFSOD). (A) No green fluorescence can be observed in myocardial tissue injected with FSOD. (B) Bright green fluorescent PKFSOD particles can be observed in the myocardium three days following ischemia-reperfusion surgery. (Blue is DAPI counter staining, white bar represents 50 μm).

Figure 4. PKSOD scavenges superoxide in the border zone following ischemia-reperfusion
 Pictures shown are representative images of dihydroethidium (DHE) fluorescence in the myocardium, imaged with identical camera settings. Individual images were quantified for red fluorescence intensity using ImageJ software in a blinded manner and represented as mean $\pm$ SEM ($n \geq 5$ per group). Only PKSOD significantly reduced DHE fluorescence 3 days following IR, with no effect of empty PK or free SOD1. * $p < 0.05$ ANOVA, followed by Dunnett's multiple comparison test.

Figure 5. PKSOD treatment decreases myocyte apoptosis

Three days after surgery, IR injury significantly increased cardiomyocyte apoptosis in the left ventricle compared to sham operated animals that was not attenuated by empty polyketal (PK) or free SOD1 treatment. In contrast, PKSOD treatment was able to significantly reduce the TUNEL-positive myocyte count. Data are expressed as mean $\pm$ SEM ($n \geq 6$ per group). * $p < 0.05$; ANOVA followed by Dunnett's multiple comparison test.

Figure 6. Effect of PKSOD on acute and chronic cardiac function

Adult male Sprague-Dawley rats subjected to sham or IR surgery with or without indicated treatments were subjected to echocardiography prior to surgery, and 3 or 21 days post-infarction. Change in fractional shortening was normalized to baseline values of each rat before surgery. (A) PKSOD treated rats had significantly improved cardiac function as compared to ischemia-reperfusion (IR) alone 3 days following infarction, with no effect of empty PK or free SOD1. (B) Only a dual treatment with PKSOD and PK-p38_i significantly improved cardiac function as compared to IR alone. No significant effect was seen with PKSOD, empty PK, or free SOD1. Data are expressed as mean $\pm$ SEM ($n \geq 10$ per group) ** $p < 0.01$, * $p < 0.05$, NS = not significant; ANOVA followed by Dunnett's multiple comparison test.